Journal de la sclérose en plaques

Court commentaire

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Court commentaire

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Court commentaire

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Court commentaire

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Court commentaire

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Perspective

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Perspective

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Mini examen

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Mini examen

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspective

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Perspective

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Mini examen

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspective

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Mini examen

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Mini examen

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

article de recherche

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

article de recherche

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

article de recherche

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

article de recherche

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Volume 11, Problème 1 (2024)

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Faits saillants de la revue

Indexé dans